Full-Time
Territory Manager
Basque Country, Cantabria, Navarra
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
Madrid, Spain
In Person
The territory covers the Basque Country, Cantabria, Navarra, and surrounding areas; travel is approximately 30%.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- A university degree is required.
- At least 3 years of experience, preferably in ophthalmology, is required.
- Excellent communication, negotiation, and presentation skills are required.
- Demonstrated ability to develop and complete sales plans is required.
- Fluency in English is required.
- Willingness to travel approximately 30% of the time is required.
- Achieve Surgical Vision product sales to new and established medical and professional accounts to meet sales objectives and increase market penetration.
- Create territory plans through the sale and servicing of multiple physician and healthcare professional accounts in the prescribed territory.
- Identify customer needs and recommend new products to address them.
- Develop customer- and product-focused presentation packages for sales.
- Follow up with customers to resolve issues and ensure satisfaction.
- Support strategic customers and key accounts while reporting to the local Sales Manager.
- Drive growth in the intraocular lenses portfolio through strategic partnerships, market analysis, and new business development.
- Define influence and decision-maker mappings and implement tailored business development plans for selected customers.
- Present the product portfolio and equipment to clients while addressing their specific needs.
- Coordinate with Sales Managers to establish and prioritize development plans for key private customers.
- Track and report action plans and sales performance, providing regular updates to senior management.
- Develop and implement account business plans in collaboration with Sales Managers and cross-functional roles.
- Manage inventory, deposits, and capital expenditures in compliance with company policies and procedures.
- Establish and maintain relationships with key decision-makers.
- Provide input to sales forecasts, report field activity, and provide feedback to management.
- Expand market share and revenue for the anterior segment portfolio, with a major focus on intraocular lenses.
- Support commercial efforts with other accounts in the region.
- Work with internal teams to align strategies and ensure product-market fit.
- Supervise sales performance and adjust strategies to meet targets.
- Provide reports on market conditions, sales performance, and pivotal initiatives to senior management.
- Manage accounts, analyze territories, and develop action plans.
- Promote products and manage tenders.
- Market Access experience would be an advantage.
- Proficiency in customer relationship management software and Microsoft Office Suite is preferred.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales hit $25.3 billion, and guidance rose to $101.1 billion.
- Tremfya surged 72.5% to $2 billion, proving the immunology replacement strategy works.
- August 21, 2026 TECVAYLI-daratumumab approval and MONARCH QUEST 3 clearance expand pipelines.
What critics are saying
- July 2026 talc settlement needs 95% claimant approval; failure reopens 76,000 claims.
- Stelara biosimilars keep crushing legacy revenue, and replacement drugs must sustain 2027 growth.
- MedTech growth lagged Q2 expectations; Intuitive Surgical and Medtronic intensify hospital-buying competition.
What makes Johnson & Johnson unique
- J&J spans pharmaceuticals, MedTech, and cash-generating scale after Kenvue’s 2023 spinout.
- Tremfya, Darzalex, Carvykti, and Tecvayli offset Stelara’s 55% Q2 decline.
- AAA balance sheet and 64-year dividend streak signal resilience through patent cliffs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.
The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.
Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.
Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.
Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.